Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2024-01-10 Capital/Financing Update
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Bilan au 29 décembre 2023 du contrat de liquidité contracté avec la Société de Bourse Gilbert Dupont
Capital/Financing Update Classification · 99% confidence The document is a report titled "Bilan au 29 décembre 2023 du contrat de liquidité contracté avec la Société de Bourse Gilbert Dupont" (Balance sheet as of December 29, 2023, for the liquidity contract with Gilbert Dupont Stock Brokerage Firm). It details the status of a liquidity contract, including the number of shares and cash balance, and reports on trading activity (purchases and sales) during the second half of 2023. This type of disclosure relates to the company's own shares being managed under a specific agreement, often related to market making or stabilization. This activity falls under the category of 'Transaction in Own Shares' (POS), which covers share repurchase/issuance activities, even if the activity reported here is zero transactions for the period, the document's subject matter is the management of the company's own stock via a liquidity contract. It is not a general earnings release (ER), a major shareholding notification (MRQ) concerning external shareholders, or a capital change announcement (SHA) regarding a structural change, but rather a report on the status of the company's own shares held under a specific arrangement.
2024-01-10 English
Quantum Genomics enters into exclusive negotiations with ExactCure
Regulatory Filings Classification · 100% confidence The document is a press release announcing that Quantum Genomics has entered into exclusive negotiations for a merger with ExactCure. It details the rationale, key terms, indicative timeline (including an upcoming Extraordinary General Meeting to approve the transaction), and governance changes. This type of announcement, detailing a significant corporate transaction like a merger or takeover proposal, directly aligns with the definition of M&A Activity (TAR). It is not a formal regulatory filing like a 10-K, an earnings release, or a proxy statement, but a specific corporate action announcement.
2023-12-14 English
Quantum Genomics entre en négociation exclusive avec ExactCure
M&A Activity Classification · 98% confidence The document is a press release from Quantum Genomics announcing an exclusive negotiation for a merger/acquisition (rapprochement) with ExactCure. It details the terms, governance changes, financial impact (dilution, cash position), and the required shareholder vote via an Extraordinary General Meeting (AGE). This type of announcement concerning a major corporate transaction like a merger or takeover is best classified as M&A Activity (TAR). It is not a standard financial report (10-K, IR, ER) nor a simple announcement of a report (RPA).
2023-12-14 French
Quantum Genomics publie ses résultats du 1er semestre 2023
Interim / Quarterly Report Classification · 95% confidence The document is a press release announcing the financial results for the first half of 2023. It provides a summary of key financial metrics (operating income, net result, cash flow, and debt) and includes tables summarizing the financial position. While it mentions that the full audited financial statements are available on the company website, the document itself contains substantive financial data and analysis for the interim period, qualifying it as an Interim/Quarterly Report (IR) rather than a mere publication announcement (RPA). H1 2023
2023-10-24 French
Quantum Genomics Releases First-Half 2023 Financial Results
Earnings Release Classification · 95% confidence The document is a press release announcing the first-half 2023 financial results for Quantum Genomics. While it provides a summary of financial data and business updates, it explicitly states that the full audited financial statements are published elsewhere on the company's website. According to the 'Menu vs Meal' rule, this document serves as an announcement of the results rather than the full interim report itself. Therefore, it is classified as an Earnings Release (ER). H1 2023
2023-10-24 English
Quantum Genomics annonce reprendre ses discussions avec des sociétés de HealthTech à la suite de l'arrêt des négociations exclusives avec Vistacare Medical
M&A Activity Classification · 99% confidence The document is a short announcement from Quantum Genomics regarding the termination of exclusive negotiations with Vistacare Medical and the intention to resume discussions with other HealthTech companies. It also mentions the upcoming publication date for the H1 2023 results (October 24, 2023). Since this is a brief, specific corporate action announcement that doesn't fit the definitions for a full report (10-K, IR), earnings release (ER), or dividend notice (DIV), it falls best under the general category for miscellaneous regulatory announcements or corporate news that isn't covered by more specific codes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for this type of material corporate update that is not a formal financial statement or management discussion.
2023-10-17 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.